Health Trials

Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

ConditionsEfficacySafetyMegestrol AcetateAdult Subject
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorChangchun GeneScience Pharmaceutical Co., Ltd.

About this trial

To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients

Eligibility criteria

Qualifiers

Age ≥ 18 years, regardless of sex

Histologically or cytologically confirmed lung cancer

Expected survival ≥ 3 months

Female subjects of childbearing potential must have negative serum pregnancy test within 72 hours prior to randomization and must be non-lactating

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Low dose of Megestrol Acetate Oral Suspension combined with standard therapy
  • Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy
  • High dose of Megestrol Acetate Oral Suspension combined with standard therapy
  • Megestrol Acetate Oral Suspension Placebo combined with standard therapy

Treatment groups

132 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Changchun GeneScience Pharmaceutical Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov